Trials / Recruiting
RecruitingNCT06110793
A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer
A Phase Ib/II Trial of Lenvatinib Plus Pembrolizumab Plus Fulvestrant in ER-positive/ HER2- Negative Metastatic Breast Cancer
- Status
- Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 49 (estimated)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to test whether the combination of lenvatinib, pembrolizumab, and fulvestrant is a safe and effective treatment that causes few or mild side effects in people with ER+/HER2- metastatic breast cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lenvatinib | 20mg orally PO daily |
| DRUG | Pembrolizuma | 400mg IV Q6W |
| DRUG | Fulvestrant | 500mg IM Q4W |
Timeline
- Start date
- 2023-12-29
- Primary completion
- 2027-11-01
- Completion
- 2027-11-01
- First posted
- 2023-11-01
- Last updated
- 2026-03-30
Locations
7 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06110793. Inclusion in this directory is not an endorsement.